Variable | N (%) |
---|---|
Age (years), median (IQR) | 52 (45–61) |
Gender | |
 Male | 29 (37.7) |
 Female | 48 (62.3) |
ECOG performance status | |
 0 | 32 (41.6) |
 1 | 43 (55.8) |
 2 | 2 (2.6) |
Number of comorbidities | |
 0 | 33 (42.9) |
 1 | 19 (24.7) |
  ≥ 2 | 25 (32.4) |
Prior history of cancer | |
 No | 68 (88.3) |
 Yes | 9 (11.7) |
Histology | |
 Leiomyosarcoma | 32 (41.6) |
 Others | 21 (27.2) |
 Liposarcoma | 14 (18.2) |
 Synovial sarcoma | 10 (13) |
Grade | |
 I | 8 (10.4) |
 II | 16 (20.8) |
 III | 27 (35.1) |
 Not graded/recorded | 28 (36.4) |
Site of primary tumour | |
 Thorax | 6 (7.8) |
 Abdomen/pelvis | 11 (14.3) |
 Retroperitoneum | 13 (16.9) |
 Uterus | 21 (27.3) |
 Extremity | 26 (33.8) |
Site of local recurrence (n = 20) | |
 Thorax | 4 (20) |
 Abdomen/pelvis | 12 (50) |
 Retroperitoneum | 3 (15) |
 Extremity | 1 (5) |
Site of metastasis (n = 57) | |
 Brain | 1 (1.8) |
 Lung | 46 (80.7) |
 Thorax | 4 (7) |
 Liver | 15 (26.3) |
 Abdomen/pelvis | 13 (22.8) |
 Bone | 14 (24.6) |
Extent of tumour | |
 Inoperable primary tumour | 13 (16.9) |
 Locally recurrent | 13 (16.9) |
 Recurrent metastatic tumour | 44 (57.1) |
 Locally recurrent and metastasis | 7 (9.1) |